HDL particle number and size as predictors of cardiovascular disease

1However, considerable residual risk exists even at high plasma levels of HDL-C, suggesting that other HDL-associated metrics might provide better assessment of the relationship between HDL metabolism and cardiovascular disease. Moreover, a series of recent large-scale HDL-C-raising trials failed to reduce cardiovascular disease, additionally demonstrating limitations of HDL-C as a therapeutic target. Metrics of HDL functionality represent an obvious alternative to HDL-C; their reliable assessment is, however, challenging in the clinical routine, reflecting their limited use at present. Other, than HDL-C, biomarkers of HDL metabolism frequently employed in the clinic include circulating levels of apolipoprotein A-I (apoA-I, the major HDL protein), concentrations of HDL particles, and mean HDL size. Several large-scale trials have systematically evaluated potential clinical value of these biomarkers. The present article reviews data obtained for the associations between cardiovascular risk and circulating concentrations (numbers), and mean size of HDL particles in humans.

2Several studies evaluated the relationship of cardiovascular risk with total number of HDL particles in the circulation (Table 1).

3In a nested, case–control, secondary prevention Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT), elevated number of HDL particles was a significant predictor of reduced risk of coronary heart disease (CHD) in subjects treated with gemfibrozil or placebo. Indeed, increment in total HDL particle number of 1 standard deviation (SD) decreased CHD risk by 29% during a 5-year follow-up (p = 0.0001). By contrast, circulating HDL-C and apoA-I levels were unable to predict CHD events in this study (risk reduction of 5%, p = 0.42 and 9%, p = 0.18, respectively).

4Similar results were obtained in a primary prevention Multiple Risk Factor Intervention Trial (MRFIT) of CHD mortality in men at high risk of CHD. In two groups of middle-aged men who died or did not die of CHD over 18 years of follow-up, elevated total HDL particle number at baseline significantly reduced CHD death by 50% for the comparison between the top and the bottom quartiles. As in the VA-HIT study, levels of HDL-C were not associated with the endpoint (risk reduction of 0% for the same comparison).

5In a case–control European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study of apparently healthy men and women, total HDL particle concentration at baseline was significantly diminished in CHD cases relative to controls. As a consequence, HDL particle concentrations in the top quartile decreased coronary artery disease (CAD) risk by 50% relative to the bottom quartile following adjustment for plasma apoB and triglyceride levels.

6In a randomized Heart Protection Study (HPS) trial of statin and antioxidant therapy in high-risk men and women, increment in total HDL particle number of 1 SD was associated with a significant risk reduction of 11% for major occlusive coronary events after adjustment for low density lipoprotein (LDL) particle number. Associations between cardiovascular disease and plasma HDL-C and apoA-I levels were slightly weaker, albeit significant (risk reduction of 9% for each of them). Interestingly, inverse associations of other cardiac events assessed in this study with biomarkers of HDL metabolism were only significant for HDL particle number (risk reduction of 16%) but not for HDL-C and apoA-I levels (risk reduction of 6 and 8%, respectively).

7In the Multi-Ethnic Study of Atherosclerosis (MESA) which evaluated men and women without baseline CHD or lipid altering therapy, elevated number of HDL particles revealed an inverse association with both incident CHD events (significant risk reduction of 30% per 1 SD increment in the particle number) and carotid intima-media thickness (cIMT; ). These associations were not affected by adjustment for LDL particle number (risk reduction of 32% per 1 SD increment in the particle number). Plasma HDL-C concentrations revealed similar associations with CHD (significant risk reduction of 26%) and cIMT, which were, however, markedly attenuated after adjustment for plasma levels of atherogenic lipoproteins (non-significant risk reduction of 3%).

8In a randomized Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) which enrolled subjects without cardiovascular disease assigned to either rosuvastatin or placebo, on-treatment HDL particle number was significantly associated with a composite cardiovascular endpoint in subjects randomized to the statin (risk reduction of 27% per 1 SD following adjustment for traditional cardiovascular risk factors; ). Similar associations evaluated for circulating HDL-C and apoA-I levels were not significant (risk reductions of 18 and 14%, respectively). In subjects randomized to placebo, on-treatment concentrations of HDL particles, HDL-C, and apoA-I revealed similar inverse association with the endpoint (significant risk reductions of 19, 25, and 21%, respectively). Interestingly, the association between on-treatment HDL particle numbers and cardiovascular endpoint remained significant after adjustment for HDL-C levels in this study.

9HDL particles are highly heterogeneous in structure, composition, metabolism, and function. Distinct HDL subpopulations might, therefore, exert differential effects on atherosclerosis. As a consequence, plasma concentrations of specific HDL subpopulations can be hypothesized to reveal stronger associations with cardiovascular risk as compared to total HDL particle number.

10NMR measurements allow distinguishing between large (size 9.4–14.0 nm), medium (8.3–9.3 nm), and small (7.3–8.2 nm) HDL particles. Among these HDL subpopulations, levels of large HDL frequently display inverse relationships with cardiovascular risk in univariate analyses, whereas concentrations of small HDL particles typically reveal positive correlations with the risk. Circulating concentrations of large and small HDL particles as well as those of large HDL particles and total LDL particles as measured by NMR are, however, known to be negatively correlated. Such multiple confounding renders data interpretation controversial, complicating proper assessment of the relative roles of distinct HDL subpopulations in cardioprotection.

11As a comparison, particle concentrations of HDL subpopulations can be assessed by the ion mobility assay which readily separates small (7.7–10.5 nm) and large (10.5–14.5 nm) HDL. Such evaluation reveals comparable associations of small and large particles with cardiovascular risk (hazard ratios per 1 SD of 0.78 and 0.75, respectively; ).

12The inverse relationship between particle number of large HDL and cardiovascular disease is further consistent with data on plasma levels (as mg apoA-I/dl) of HDL subpopulations separated by 2D gel electrophoresis. Indeed, circulating concentrations of large alpha-1 HDL are consistently associated with reduced cardiovascular risk. On the other hand, levels of small HDL particles assessed by this methodology are frequently elevated in CHD patients. Importantly, the power of large alpha-1 HDL to predict CHD risk is typically superior to that of HDL-C in these studies.

13Mean HDL size can be regarded as an integrative measure of HDL heterogeneity and particle profile. This metric of HDL metabolism can be assessed by both NMR and ion mobility measurements and is capable of predicting cardiovascular risk. An association between mean HDL size and cardiovascular risk is typically inverse. When HDL size is used to predict incident cardiovascular disease, hazard ratios obtained are comparable to those calculated using HDL-C and can be predominantly accounted for by traditional cardiovascular risk factors. Consistent with this conclusion, adjustment for circulating concentrations of apoB and triglycerides abolished the association between mean HDL size and CAD risk in the EPIC-Norfolk study, despite reduction in this parameter in cases relative to controls.

14Interestingly, ion mobility measurements allow distinguishing between two independent components of the association between HDL size and cardiovascular disease. The first component appears to represent an atherogenic lipoprotein phenotype, which includes increased concentrations of triglycerides and small LDL, whereas the second component is related to elevated levels of small HDL particles.

15Intriguingly, very high mean HDL size can be paradoxically associated with elevated cardiovascular risk as observed in the EPIC-Norfolk study after multiple adjustment; this association resembles those reported between cardiovascular disease and very high levels of HDL-C as observed, for example, in the IDEAL study.

16Therapeutic interventions aimed at increasing HDL-C levels, correcting atherogenic dyslipidemia, and reducing cardiovascular risk may markedly impact HDL particle concentrations. Thus, both niacin and cholesteryl ester transfer protein (CETP) inhibitors potently raise HDL-C and preferentially increase circulating levels of large HDL, augmenting mean HDL size. By contrast, effects of niacin and CETP inhibitors on total number of HDL particles are weaker, consistent with their weaker effects on plasma concentrations of apoA-I.

17Treatment with statins appears to result in comparable elevations in HDL-C and total HDL particle number. On the other hand, HDL-C-raising effects of fibrates are typically accompanied by preferential elevation of circulating levels of small HDL.

18Available data reveal that diminished HDL particle number can be superior to reduced HDL-C levels in terms of cardiovascular risk prediction. This conclusion is supported by the results of the large-scale VA-HIT, MRFIT, HPS, MESA, and JUPITER trials. Measurements of circulating concentrations of HDL particles can, therefore, be useful to improve clinical assessment of cardiovascular risk. This approach can also contribute to the evaluation of novel HDL-targeted therapies, which include CETP inhibitors, peroxisome proliferator-activated receptor (PPAR) activators, and reconstituted HDL.

19Further improvement in the evaluation of cardiovascular risk can be provided by in-depth analyses of the HDL particle profile. Although clinical relevance of circulating concentrations of HDL subpopulations needs to be firmly established, the negative association between the number of large HDL particles and cardiovascular risk suggests that clinical evaluation of the HDL particle profile can be useful.

20Diminished mean HDL size represents another biomarker of HDL metabolism associated with cardiovascular disease in large-scale clinical studies. However, available data indicate that this relationship is secondary to those established for plasma levels of HDL particles, HDL-C and large HDL; indeed, HDL-C is primarily carried in the circulation by large, buoyant, lipid-rich HDL.

21The epidemiological data thereby suggest that HDL particle number can be superior to HDL-C as a therapeutic target. This conclusion is consistent with the capacity of all HDL particles to exert a variety of atheroprotective biological activities, reflecting a wide spectrum of molecular protein, and lipid species present in HDL. High compositional heterogeneity of HDL directly results in functional heterogeneity among HDL particles, with small, dense, and protein-rich HDL typically displaying potent biological activities. The relative importance of different biological activities of HDL for atheroprotection remains presently unclear, raising a question of the proper evaluation of HDL function in vitro. Measurement of any individual HDL activity will obviously provide only limited information on all the aspects of the functionality of the circulating HDL pool. Evaluation of total number of circulating HDL particles may provide a surrogate biomarker reflecting anti-atherogenic HDL function, assuming a proportional association between the two. This hypothesis will require rigorous assessment in clinical and epidemiological studies of HDL-targeted therapies, which have failed to provide unequivocal data in this regard up to now.

22The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.